Thermo Fisher Scientific(TMO) - 2025 Q4 - Earnings Call Transcript

Financial Performance - In Q4 2025, revenue grew 7% year-over-year to $12.21 billion, while adjusted operating income increased 6% to $2.88 billion [5][25] - For the full year 2025, revenue grew 4% to $44.56 billion, and adjusted operating income also grew 4% to $10.11 billion [6][25] - Adjusted EPS for Q4 was $6.57, an 8% increase, and for the full year, it was $22.87, a 5% increase [6][25] Business Segment Performance - In the Life Science Solutions segment, Q4 revenue increased 13% year-over-year, with organic growth of 4%, driven by the bioproduction business [32] - The Analytical Instruments segment saw a 1% increase in revenue for both Q4 and the full year, with adjusted operating income decreasing 12% in Q4 due to tariffs and related FX impacts [33] - Specialty Diagnostics reported a 5% revenue growth in Q4, with adjusted operating income increasing 19% [34] - The Laboratory Products and Biopharma Services segment experienced a 7% revenue increase in Q4, with adjusted operating income rising 12% [35] Market Performance - In Q4, North America and Asia Pacific grew low single digits, while Europe grew mid single digits; China experienced a low single-digit decline [26] - For the full year, North America and Asia Pacific also grew low single digits, with China declining mid single digits [26] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [10] - In 2025, the company launched several high-impact products, enhancing its competitive position and customer relevance [10][12] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, aim to enhance productivity and innovation [14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with a revenue guidance range of $46.3 billion to $47.2 billion, reflecting 4%-6% growth [22][37] - The company anticipates continued share gain momentum and strong earnings growth, with adjusted EPS guidance of $24.22 to $24.80, representing 6%-8% growth [22][37] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [16][30] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [18][39] Q&A Session Summary Question: Can you discuss the acceleration in organic growth guidance for 2026? - Management indicated that the guidance assumes market conditions similar to 2025, with expectations for improved conditions leading to 3%-4% organic growth [49][50] Question: How are pharma budgets looking for 2026? - Management noted positive sentiment in pharma spending, with confidence in navigating government regulations and excitement around pipelines [58][60] Question: What is the outlook for the Pharma Services business? - The company is well-positioned in the Pharma Services sector, particularly in sterile fill finish, with heightened demand relative to industry capacity [66]